Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease | Zendy

Davangere P. Devanand | Zendy; Jacobo Mintzer | Zendy; Susan K. Schultz | Zendy; Howard Andrews | Zendy; David L. Sultzer | Zendy; Danilo de la Pena | Zendy; Sanjay Gupta | Zendy; Sylvia Colon | Zendy; Corbett Schimming | Zendy; Gregory H. Pelton | Zendy; Bruce Levin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease

Author(s) -

Davangere P. Devanand,

Jacobo Mintzer,

Susan K. Schultz,

Howard Andrews,

David L. Sultzer,

Danilo de la Pena,

Sanjay Gupta,

Sylvia Colon,

Corbett Schimming,

Gregory H. Pelton,

Bruce Levin

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1114058

Subject(s) - risperidone , discontinuation , medicine , hazard ratio , placebo , antipsychotic , randomization , psychosis , extrapyramidal symptoms , atypical antipsychotic , randomized controlled trial , schizophrenia (object oriented programming) , confidence interval , psychiatry , surgery , alternative medicine , pathology

Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research